ID   HAL-01
AC   CVCL_1242
SY   HAL-O1; HAL01; HAL-1; HALO1
DR   BTO; BTO:0004942
DR   CLO; CLO_0050976
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN01821626
DR   BioSample; SAMN03473501
DR   cancercelllines; CVCL_1242
DR   Cell_Model_Passport; SIDM00289
DR   ChEMBL-Cells; CHEMBL3308233
DR   ChEMBL-Targets; CHEMBL2366142
DR   CLS; 305140
DR   Cosmic; 949153
DR   Cosmic; 996300
DR   Cosmic; 998738
DR   Cosmic; 999742
DR   Cosmic; 1037744
DR   Cosmic-CLP; 949153
DR   DepMap; ACH-002241
DR   DSMZ; ACC-610
DR   DSMZCellDive; ACC-610
DR   EGA; EGAS00001000978
DR   GDSC; 949153
DR   GEO; GSM1669838
DR   GEO; GSM5137716
DR   IARC_TP53; 27557
DR   KCB; KCB 94011YJ
DR   LINCS_LDP; LCL-1046
DR   PharmacoDB; HAL01_441_2019
DR   PRIDE; PXD023662
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1242
DR   RCB; RCB0540
DR   Wikidata; Q54872387
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   DOI=10.11418/jtca1981.15.4_211;
RX   PubMed=1516826;
RX   PubMed=2027299;
RX   PubMed=9680106;
RX   PubMed=10739008;
RX   PubMed=11226526;
RX   PubMed=14504097;
RX   PubMed=20147975;
RX   PubMed=20164919;
RX   PubMed=20519628;
RX   PubMed=20575032;
RX   PubMed=27397505;
RX   PubMed=29786757;
RX   PubMed=30894373;
RX   PubMed=35124168;
RX   PubMed=35354797;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 32 hours (PubMed=2027299); ~48 hours (DSMZ=ACC-610).
CC   Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; Sanger).
CC   Sequence variation: Gene fusion; HGNC; 4977; HLF + HGNC; 11633; TCF3; Name(s)=TCF3-HLF, E2A-HLF; Note=In frame (PubMed=1516826).
CC   Sequence variation: Mutation; HGNC; 7978; NR3C1; Simple; p.Arg366Lysfs*8 (c.1096dup); Zygosity=Heterozygous (PubMed=35124168).
CC   Sequence variation: Mutation; HGNC; 7978; NR3C1; Simple; p.Arg477Gly (c.1429C>G) (p.Arg478Gly, c.1432C>G); Zygosity=Heterozygous (PubMed=35124168).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0.89%; East Asian, North=78.59%; East Asian, South=19.2%; South Asian=0%; European, North=0%; European, South=1.33% (PubMed=30894373).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): Cosmic-CLP; DSMZ; RCB
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11
ST   D16S539: 9,11
ST   D18S51: 13,14
ST   D19S433: 12,14
ST   D21S11: 29
ST   D2S1338: 18,24
ST   D3S1358: 15
ST   D5S818: 12,13
ST   D7S820: 10,12
ST   D8S1179: 13,15
ST   FGA: 20,22
ST   Penta D: 9,10
ST   Penta E: 11,17
ST   TH01: 6,8
ST   TPOX: 8,11
ST   vWA: 16,17
DI   NCIt; C8644; B acute lymphoblastic leukemia
DI   ORDO; Orphanet_99860; Precursor B-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   17Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 37
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   DOI=10.11418/jtca1981.15.4_211;
RA   Matsuo Y., Okochi A., Ariyasu T., Iimura E., Ohno T.;
RT   "Identification of cell lines with variable numbers of tandem repeat
RT   (VNTR) amplified by polymerase chain reaction.";
RL   Tissue Cult. Res. Commun. 15:211-219(1996).
//
RX   PubMed=1516826; DOI=10.1101/gad.6.9.1608;
RA   Hunger S.P., Ohyashiki K., Toyama K., Cleary M.L.;
RT   "Hlf, a novel hepatic bZIP protein, shows altered DNA-binding
RT   properties following fusion to E2A in t(17;19) acute lymphoblastic
RT   leukemia.";
RL   Genes Dev. 6:1608-1620(1992).
//
RX   PubMed=2027299;
RA   Ohyashiki K., Fujieda H., Miyauchi J., Ohyashiki J.H., Tauchi T.,
RA   Saito M., Nakazawa S., Abe K., Yamamoto K., Clark S.C., Toyama K.;
RT   "Establishment of a novel heterotransplantable acute lymphoblastic
RT   leukemia cell line with a t(17;19) chromosomal translocation the
RT   growth of which is inhibited by interleukin-3.";
RL   Leukemia 5:322-331(1991).
//
RX   PubMed=9680106; DOI=10.1016/S0145-2126(98)00050-2;
RA   Matsuo Y., Drexler H.G.;
RT   "Establishment and characterization of human B cell precursor-leukemia
RT   cell lines.";
RL   Leuk. Res. 22:567-579(1998).
//
RX   PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Frequent microsatellite instability and BAX mutations in T cell acute
RT   lymphoblastic leukemia cell lines.";
RL   Leuk. Res. 24:255-262(2000).
//
RX   PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Corrigendum to: Frequent microsatellite instability and BAX mutations
RT   in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24
RT   (2000),255-262.";
RL   Leuk. Res. 25:275-278(2001).
//
RX   PubMed=14504097; DOI=10.1182/blood-2003-02-0418;
RA   Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R.,
RA   Tsuchida M., Sugita K., Ida K., Hayashi Y.;
RT   "FLT3 mutations in the activation loop of tyrosine kinase domain are
RT   frequently found in infant ALL with MLL rearrangements and pediatric
RT   ALL with hyperdiploidy.";
RL   Blood 103:1085-1088(2004).
//
RX   PubMed=20147975; DOI=10.1038/leu.2010.8;
RA   Akahane K., Inukai T., Inaba T., Kurosawa H., Look A.T., Kiyokawa N.,
RA   Fujimoto J., Goto H., Endo M., Zhang X., Hirose K., Kuroda I.,
RA   Honna H., Kagami K., Goi K., Nakazawa S., Sugita K.;
RT   "Specific induction of CD33 expression by E2A-HLF: the first evidence
RT   for aberrant myeloid antigen expression in ALL by a fusion
RT   transcription factor.";
RL   Leukemia 24:865-869(2010).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20519628; DOI=10.1182/blood-2009-09-244673;
RA   Hirose K., Inukai T., Kikuchi J., Furukawa Y., Ikawa T., Kawamoto H.,
RA   Oram S.H., Gottgens B., Kiyokawa N., Miyagawa Y., Okita H.,
RA   Akahane K., Zhang X.-C., Kuroda I., Honna H., Kagami K., Goi K.,
RA   Kurosawa H., Look A.T., Matsui H., Inaba T., Sugita K.;
RT   "Aberrant induction of LMO2 by the E2A-HLF chimeric transcription
RT   factor and its implication in leukemogenesis of B-precursor ALL with
RT   t(17;19).";
RL   Blood 116:962-970(2010).
//
RX   PubMed=20575032; DOI=10.1002/ajh.21738;
RA   Inukai T., Zhang X.-R., Kameyama T., Suzuki Y., Yoshikawa K., Kuroda I.,
RA   Nemoto A., Akahane K., Sato H., Goi K., Nakamoto K., Hamada J.-i.,
RA   Tada M., Moriuchi T., Sugita K.;
RT   "A specific linkage between the incidence of TP53 mutations and type
RT   of chromosomal translocations in B-precursor acute lymphoblastic
RT   leukemia cell lines.";
RL   Am. J. Hematol. 85:535-537(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29786757; DOI=10.1007/s12185-018-2474-7;
RA   Tomoyasu C., Imamura T., Tomii T., Yano M., Asai D., Goto H.,
RA   Shimada A., Sanada M., Iwamoto S., Takita J., Minegishi M., Inukai T.,
RA   Sugita K., Hosoi H.;
RT   "Copy number abnormality of acute lymphoblastic leukemia cell lines
RT   based on their genetic subtypes.";
RL   Int. J. Hematol. 108:312-318(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35124168; DOI=10.1016/j.jsbmb.2022.106068;
RA   Tamai M., Kasai S., Akahane K., Thu T.N., Kagami K., Komatsu C.,
RA   Abe M., Watanabe A., Goi K., Miyake K., Inaba T., Takita J., Goto H.,
RA   Minegishi M., Iwamoto S., Sugita K., Inukai T.;
RT   "Glucocorticoid receptor gene mutations confer glucocorticoid
RT   resistance in B-cell precursor acute lymphoblastic leukemia.";
RL   J. Steroid Biochem. Mol. Biol. 218:106068.1-106068.12(2022).
//
RX   PubMed=35354797; DOI=10.1038/s41467-022-29224-5;
RA   Leo I.R., Aswad L., Stahl M., Kunold E., Post F., Erkers T.,
RA   Struyf N., Mermelekas G., Joshi R.N., Gracia-Villacampa E.,
RA   Ostling P., Kallioniemi O.-P., Pokrovskaja Tamm K., Siavelis I.,
RA   Lehtio J., Vesterlund M., Jafari R.;
RT   "Integrative multi-omics and drug response profiling of childhood
RT   acute lymphoblastic leukemia cell lines.";
RL   Nat. Commun. 13:1691.1-1691.19(2022).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//